Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Nov 8;11(11):CD005626.
doi: 10.1002/14651858.CD005626.pub4.

Rutosides for prevention of post-thrombotic syndrome

Joanne R Morling  1 , Su Ern Yeoh, Dinanda N Kolbach
Affiliations

Rutosides for prevention of post-thrombotic syndrome

Joanne R Morling et al. Cochrane Database Syst Rev. .

Abstract

Background: Post-thrombotic syndrome (PTS) is a long-term complication of deep venous thrombosis (DVT) that is characterised by pain, swelling, and skin changes in the affected limb. One in three patients with DVT will develop post-thrombotic sequelae within five years. The current standard care for the prevention of PTS following DVT is elastic compression stockings. Rutosides are a group of compounds derived from horse chestnut (Aesculus hippocastanum), a traditional herbal remedy for treating oedema formation in chronic venous insufficiency (CVI). However, it is not known whether rutosides are effective and safe in the prevention of PTS. This is the second update of the review first published in 2013.

Objectives: To determine the effectiveness and safety of rutosides for prevention of post-thrombotic syndrome (PTS) in patients with deep vein thrombosis (DVT), compared to placebo, no intervention, or reference medication.

Search methods: The Cochrane Vascular Information Specialist searched the Cochrane Vascular Specialised Register, CENTRAL, MEDLINE, Embase and CINAHL databases and World Health Organization International Clinical Trials Registry Platform and ClinicalTrials.gov trials registers to 21 August 2018.

Selection criteria: We planned to include trials of rutosides versus any alternative (placebo, no intervention, or reference medication) in the prevention of PTS in patients with DVT.

Data collection and analysis: Two review authors independently assessed studies for inclusion and intended to extract information from the trials.

Main results: No studies were identified comparing rutosides versus any alternative in the prevention of PTS.

Authors' conclusions: As there were no studies identified in this review there is currently insufficient evidence to determine the effectiveness and safety of rutosides for prevention of PTS in patients with DVT. Some studies suggest that rutosides may provide short-term relief of PTS symptoms. However, there is nothing published on their use as a preventative therapy for PTS. High quality randomised controlled trials of rutoside versus any alternative are required to build the evidence base in this area.

PubMed Disclaimer

Conflict of interest statement

JM: declared that she is currently receiving a MRC Clinical Scientist Fellowship grant and this does not conflict with this review SEY: none known DK: none known

Figures

1
1
Study flow diagram.
See this image and copyright information in PMC

Update of

References

References to studies excluded from this review

Monreal 1997 {published data only}
    1. Monreal M, Callejas JM, Martorell A, Sahuquillo JC, Contel E. Prevention of post‐thrombotic syndrome with hidrosmina: a prospective pilot study. Phlebology 1997;12(1):21‐4.

Additional references

Appelen 2017
    1. Appelen D, Loo E, Prins MH, Neumann MHAM, Kolbach DN. Compression therapy for prevention of post‐thrombotic syndrome. Cochrane Database of Systematic Reviews 2017, Issue 9. [DOI: 10.1002/14651858.CD004174.pub3] - DOI - PMC - PubMed
Atkins 2004
    1. Atkins D, Best D, Briss PA, Eccles M, Falck‐Ytter Y, Flottorp S, et al. Grading quality of evidence and strength of recommendations. British Medical Journal 2004;328(7454):1490‐4. - PMC - PubMed
Bombardelli 1996
    1. Bombardelli E, Morazzoni P, Griffini A. Aesculus hippocastanum L. Fitoterapia 1996;67(6):483‐511.
Cesarone 2005
    1. Cesarone MR, Belcaro G, Pellegrini L, Ledda A, Vinciguerra G, Ricci A, et al. HR, 0‐(beta‐hydroxyethyl)‐rutosides; (Venoruton): rapid relief of signs/symptoms in chronic venous insufficiency and microangiopathy: a prospective, controlled study. Angiology 2005;56(2):165‐72. - PubMed
Facino 1995
    1. Facino RM, Carini M, Stefani R, Aldini G, Saibene L. Anti‐elastase and anti‐hyaluronidase activities of saponins and sapogenins from Hedera helix, Aesculus hippocastanum, and Ruscus aculeatus: factors contributing to their efficacy in the treatment of venous insufficiency. Archiv der Pharmazie 1995;328(10):720‐4. - PubMed
GRADEpro GDT 2015 [Computer program]
    1. McMaster University (developed by Evidence Prime). GRADEpro GDT. Version accessed 10 October 2018. Hamilton (ON): McMaster University (developed by Evidence Prime), 2015.
Guillaume 1994
    1. Guillaume M, Padioleau F. Veinotonic effect, vascular protection, anti‐inflammatory and free radical scavenging properties of horse chestnut extract. Arzneimittelforschung 1994;44(1):25‐35. - PubMed
Guyatt 2011
    1. Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al. GRADE guidelines: 1. Introduction GRADE evidence profiles and summary of findings tables. Journal of Clinical Epidemiology 2011;64:383‐94. - PubMed
Higgins 2011
    1. Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
Iafrati 1994
    1. Iafrati MD, Welch H, O'Donnell TF, Belkin M, Umphrey S, McLaughlin R. Correlation of venous noninvasive tests with the Society of Vascular Surgery/International Society for Cardiovascular Surgery clinical classification of chronic venous insufficiency. Journal of Vascular Surgery 1994;19(6):1001‐7. - PubMed
Lefebvre 2011
    1. Lefebvre C, Manheimer E, Glanville J. Chapter 6: Searching for studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
Lorenz 1960
    1. Lorenz D, Marek ML. Das therapeutische wirksame Prinzip der Rosskastanie (Aesculus hippocastanum). Arzneimittelforschung 1960;10:263‐72.
Meissner 2002
    1. Meissner MH, Zierler BK, Bergelin RO, Chandler WL, Strandness DE Jr. Coagulation, fibrinolysis, and recanalization after acute deep venous thrombosis. Journal of Vascular Surgery 2002;35(2):278‐85. - PubMed
Morling 2018
    1. Morling JR, Yeoh SE, Kolbach DN. Rutosides for treatment of post‐thrombotic syndrome. Cochrane Database of Systematic Reviews 2018, Issue 11. [DOI: 10.1002/14651858.CD005625.pub4] - DOI - PMC - PubMed
Moyses 1987
    1. Moyses C, Cederholm‐Williams SA, Michel CC. Haemoconcentration and accumulation of white cells in the feet during venous stasis. International Journal of Microcirculation: Clinical and Experimental 1987;5(4):311‐20. - PubMed
Partsch 1991
    1. Partsch H. Compression therapy of the legs. A review. Journal of Dermatologic Surgery and Oncology 1991;17(10):799‐805. - PubMed
Pittler 2012
    1. Pittler MH, Ernst E. Horse chestnut seed extract for chronic venous insufficiency. Cochrane Database of Systematic Reviews 2012, Issue 11. [DOI: 10.1002/14651858.CD003230.pub4] - DOI - PMC - PubMed
Prandoni 1996
    1. Prandoni P, Lensing AW, Cogo A, Cuppini S, Villalta S, Carta M, et al. The long‐term clinical course of acute deep venous thrombosis. Annals of Internal Medicine 1996;125(1):1‐7. - PubMed
Sarin 1993
    1. Sarin S, Andaz A, Shields DA, Scurr JH, Coleridge Smith PD. Neutrophil activation in venous disease. Journal of Vascular Surgery 1993;17:444.
Schrader 1995
    1. Schrader E, Schwankl W, Sieder C, Christoffel V. Comparison of the bioavailability of beta‐aescin after single oral administration of two different drug formulations containing an extract of horse‐chestnut seeds [Vergleichende Untersuchung zur Bioverfügbarkeit von ß‐Aescin nach oraler Einmalverabreichung zweier Rosskastaniensamenextrakt enthaltender, galenisch unterschiedlicher Darreichungsformen]. Pharmazie 1995;50(9):623‐7. - PubMed
Thomas 1988
    1. Thomas PR, Nash GB, Dormandy JA. White cell accumulation in dependent legs of patients with venous hypertension: a possible mechanism for trophic changes in the skin. British Medical Journal 1988;296(6638):1693‐5. - PMC - PubMed
Widmer 1985
    1. Widmer LK, Zemp E, Widmer TM, Schmitt HE, Brandenberg E, Voelin R, et al. Late results in deep vein thrombosis of the lower extremity. Vasa 1985;14(3):264‐8. - PubMed

References to other published versions of this review

Kolbach 2006
    1. Kolbach DN, Prins MH. Rutosides for prevention of post thrombotic syndrome. Cochrane Database of Systematic Reviews 2006, Issue 1. [DOI: 10.1002/14651858.CD005626] - DOI - PMC - PubMed
Morling 2013
    1. Morling JR, Yeoh SE, Kolbach DN. Rutosides for prevention of post‐thrombotic syndrome. Cochrane Database of Systematic Reviews 2013, Issue 4. [DOI: 10.1002/14651858.CD005626.pub2] - DOI - PubMed
Morling 2015
    1. Morling JR, Yeoh SE, Kolbach DN. Rutosides for prevention of post‐thrombotic syndrome. Cochrane Database of Systematic Reviews 2015, Issue 9. [DOI: 10.1002/14651858.CD005626.pub3] - DOI - PubMed

Publication types

MeSH terms